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Abstract: This report presents a new library of organometallic 
iridium(III) compounds of the type [Cp*IrCl(N,O)] (Cp* = 
pentamethylcyclopentadienyl and N,O = a functionalized E-
ketoiminato ligand) showing moderate to high cytotoxicity against a 
range of cancer cell lines. All compounds show increased activity 
towards colorectal cancer, with preferential activity observed against 
the immortalized p53-null colorectal cell line, HCT116 p53-/-, with 
sensitivity factors (SF) up to 26.7. Additionally, the compounds have 
excellent selectivity for cancerous cells when tested against normal 
cell types, with selectivity ratios (SR) up to 35.6, contrary to that of 
cisplatin which is neither selective nor specific for cancerous cells (SF 
= 0.43 and SR = 0.7-2.3). This work provides a preliminary 
understanding of the cytotoxicity of iridium compounds in the absence 
of p53 and has potential applications in treatment of cancers for which 
the p53 gene is absent or mutant. 
After the discovery of the therapeutic effects of cisplatin in 1965, 
the drug was marketed and introduced into clinical use,[1] and over 
50% of anticancer therapies use cisplatin or its platinum 
derivatives.[2] However, the increase in cell resistance to platinum 
and undesired side-effects from a lack of cancer targeting has led 
research towards new drug candidates based on different 
transition metals.[3] Generally, metal-based therapeutics have 
many advantages over traditional organic compounds, as the 
metals can have variable oxidation states which can be used to 
selectively target the different cell environments, and the 
FRPSRXQGV¶ properties can be easily tuned by incorporating 
different biologically relevant ligands.[4] Since the therapeutic 
properties of titanocene dichloride were reported,[5,6] there has 
been a significant increase in the number of organometallic drug 
candidates which have shown high potency, cancer cell selectivity 
and even activity towards cisplatin-resistant cells.[7] During the 
later 1990s, much work was conducted using ruthenium 
organometallic complexes, with the first complex 
[(arene)Ru(N,N)X] (N,N = ethylenediamine, X = halide) showing 
effective growth inhibition of cancer cells and the formation of 
strong monofunctional adducts with DNA.[8,9] 
To date, the design of organometallic iridium compounds as 
potential therapeutics is still in its infancy, and this is in part due 
to the reported inert nature of the low-spin d6 metal ion. This is 
particularly well characterized for the slow exchange of aqua 
ligands on [Ir(H2O)6]3+, which is known to take hundreds of 
years.[10] On the other hand, it is also known that water exchange 
in [Cp*Ir(H2O)3]2+ is approximately 1014 times faster.[11] Sadler et 
al. first reported the half-sandwich iridium(III) complexes of the 
type [CpIr(X,Y)Cl]0/+ (Cp = functionalized cyclopentadienyl and 
X,Y = N,N-dimethylphenylazopyridine), in which the complexes 
are labile towards hydrolysis and inactive anti-cancer agents.[12] 
However, when the Cp ligand was extended to contain more 
phenyl rings, the complexes exhibited intercalation with DNA 
bases and had good potency towards cancerous cells. 
Additionally, when changing the chelating N,N-ligand for a 
chelating N,C-ligand, the extension to the Cp ligand was no 
longer required for the complex to be cytotoxic, highlighting the 
importance of the bidentate ligand. Such compounds were shown 
to have polypharmacologic properties, which increase the amount 
of reactive oxygen species (ROS), damage DNA and disrupt 
protein synthesis.[12,13] Dyson et al. then reported that the 
cyclopentadienyl ligands can stabilize Ir(III), and confer kinetic 
lability on trans monodentate halide ligands, again showing that 
the addition of phenyl substituents on the Cp ring has a major 
HႇHFW RQ WKH EHKDYLRU RI FRPSOH[HV ,ULGLXP RUJDQRPHWDOOLF
compounds incorporating the naturally occurring curcumin, both 
with and without their well-known PTA (1,3,5-triaza-7-
phosphatricyclo-[3.3.1.1]decane) ligands, were reported, 
however, these complexes were less active than curcumin 
alone.[14]  
More recently, researchers have reported on iridium COD (COD 
= 1,5-cyclooctadiene) compounds showing good in vitro potential. 
Metzler-Nolte et al. reported iridium(I) COD compounds with the 
incorporation of NHCs (N-heterocycle carbenes), in which they 
suggest that the neutral complexes cause cell death through 
interactions with proteins, whereas the cationic complexes are 
likely to exert their biological effect without reacting with other 
cellular components. The cationic compounds have high 
nanomolar cytotoxicity, with high stability towards oxidation and 
no reaction with model proteins. Though in the presence of 
excess H2O2, the Ir(I) slowly oxidizes to Ir(III), increasing its 
cytotoxic potential, by inducing redox chemical effects and 
allowing for a better coordination and ultimately changing the 
potential cellular mode of action by changing the oxidation 
state.[15] Contrarily, the work by Gasser et al. has highlighted new 
iridium(III) COD, showing different cytotoxic potentials depending 
on the solvent used during the assays (DMSO vs. DMF).[16] Both 
works show that the cellular modes of action are hard to identify, 
and small changes in either the experimental setup or the cellular 
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environment may induce a drastic change in the compounds 
potential as a drug. 
In 2012, alongside its ruthenium analogue, the authors reported 
the organometallic iridium(III) complex A (Figure 1), which 
incorporates a E-ketoiminato ligand.[17] The cytotoxicity against a 
range of cell lines showed that the binding mode of the chelating 
ligand affects the activity, whereby (N,O) > (O,O) > (N,N). Simple 
E-diketonate (O,O) iridium(III) complexes similar to B (Figure 1) 
have been shown to be potent antibacterial agents,[18] however, 
we observed a 16-fold decrease in cytotoxicity when changing the 
ligand from a E-ketoiminato (N,O) (A) to a E-diketonato (O,O) (B) 
or eliminating the aniline ring from the E-ketoiminato ligand (C) 
(Figure 1).[19] To date, the E-ketoiminato complexes are the most 
promising class of ligands, exhibiting high cytotoxicity against a 
range of cell lines and inducing dose-dependent single strand 
DNA breakage.[19] Additionally, organometallic iridium(III) 
complexes with different length alcohol tethers introduced onto 
the Cp substituent have been reported, in which the cytotoxicity 
increased with tether length, but was independent of the 
chelation.[20]  
Figure 1. Previously reported iridium complexes of the type [Cp*IrCl(N,O)]; A. 
N,O = phenyl-E-ketoiminato, B. E-diketonato and C. NH-E-ketoiminato, with IC50 
values stated against colorectal cancer type HT-29. 
Herein, we have synthesized a library of compounds related to 
compound A. This range of compounds were designed using our 
understanding of similar ruthenium complexes, in which the 
complexes showed promising cytotoxicity against the colorectal 
cancer cell line HT-29.[19] The compounds reported here are 
selective for colorectal cancer, especially immortalized colorectal 
cancers with null p53 function. As the p53 plays a role in apoptosis, 
and the increased activity of these compounds against null-p53 
cells gives rise to a potential p53-independent pathway of cell 
death. Additionally, we report chemosensitivity studies against 
normal cell types, which show these compounds to be non-toxic 
towards normal cells, contrary to that of cisplatin which remains 
cytotoxic. There are reports on small molecules which target the 
p53 pathway,[21] ruthenium compounds which have a greater 
radio-sensitizing activity in p53-wildtype cells compared with p53-
null or p53-mutated,[22] and novel ruthenium compounds which 
induce S-phase arrest and apoptosis in HepG2 cells through a 
p53-independent pathway.[23] Yet to date, very little work has been 
reported on iridium complexes that are both selective towards 
cancer cells types and are active through p53-independent 
pathways. However, work by Sadler et al. has begun to underpin 
the modes of action of such iridium organometallic compounds, 
including increases in ROS, DNA damage, and disruption of 
protein synthesis[24] 
Results 
Synthesis and Characterization of Iridium(III) Metal 
Complexes 
The E-ketoiminato ligands and their respective iridium complexes 
were synthesized according to our previous method (Scheme 
1).[17,19] The iridium dimer, [Cp*IrCl2]2 (0.5 eq.) was added to a 
stirring mixture of functionalized ligand (N,O) (1 eq.) and 
triethylamine (1 eq.) in dichloromethane at room temperature. 
Complexes of the type [Cp*IrCl(N,O)] were isolated by removing 
the solvent by vacuum and recrystallization from methanol to yield 
analytically pure products in moderate yields. All complexes have 
been characterized by 1H and 13C{1H} NMR spectroscopy, mass 
spectrometry, single crystal X-ray diffraction and microanalysis.  
Scheme 1. Synthesis of E-ketoiminato iridium(III) complexes 1-9, [Cp*IrCl(N,O)] 
(N,O = functionalized E-ketoiminato ligand). 
Orange/ red single crystals of complexes 1-4 and 6-9, suitable for 
X-ray crystallographic analysis, were obtained from slow 
evaporation from the methanolic solutions. X-ray solutions were 
performed in a triclinic (1-4, 6 and 7), monoclinic (8) or 
orthorhombic (9) space group, and the crystallographic data is 
present in Table S1 (1-4) and Table S2 (6-9). All of the bond 
lengths and bond angles around the metal center show the 
geometry expected for pseudo octahedral complexes, which are 
common for these half-sandwich structures (Tables S3-S6). The 
angles between the metal and the pseudo equatorial ligands are 
in the range of 83.2(2) - 89.70(19)°, with the rema ining three 
coordination sites occupied by the Cp* ligand and the angles 
observed axial to the pseudo equatorial ligand range between 
97.26 - 136.51°. Molecular structures for complexes 1-4 and 6-9 
are presented in Figure 2, with displacement ellipsoids placed at 
the 50% probability level and hydrogen atoms omitted for clarity. 
Generally, moderate yields are obtained from these reactions and 
the lower yields have been attributed to the presence of the by-
product [Cp*IrCl2(an)] (an = aniline, NH2C6H5), which 
recrystallized from several reactions. This structure was 
confirmed by NMR spectroscopy and a cell check against the 
CCDC database. 
Chemosensitivity Studies 
Chemosensitivity studies were conducted against human colon 
colorectal carcinomas p53-wildtype (HCT116 p53+/+) and p53-
null (HCT116 p53-/-), human pancreas carcinoma (MIA PaCa-2),  
Figure 2 Molecular structures for complexes 1-4 and 6-9, hydrogen atoms are 






normal human prostate cells (PNT2) and human lung carcinoma 
(A549). In order to assess selectivity towards cancerous cells, the 
compounds were screened against normal prostate (PNT2) and 
normal retinal epithelial cells (ARPE-19). The HCT116 cells are 
human colorectal cancer cell lines that are genetically identical 
(isogenic) except for the presence or absence of functional p53.[25] 
All cells were firstly incubated for 120 h with compounds 1-9 or 
cisplatin for reference, and all E-ketoiminato ligands were tested 
and are inactive at the tested threshold concentration (IC50 > 100 
PM). Additionally, the by-product [Cp*IrCl2(an)] was isolated and 
tested, and is also inactive at the tested threshold concentration 
(IC50 > 100 PM). The results are shown Table 1 and Figure S1, 
and highlight a general trend whereby compounds 1-9 have low 
to no activity against MIA PaCa-2 or A549 cells, and are > 8 times 
less active than cisplatin. The most significant results are 
observed against colorectal cancer cells, whereby compounds 1-
9 all show an increased cytotoxicity towards the isogenic HCT116 
cell lines, in particular towards the p53-null line, HCT116 p53-/-. 
This is the opposite trend observed for cisplatin, which is more 
cytotoxic towards the p53-wildtype cells, HCT116 p53+/+. The 
HCT116 p53-/- are immortalized, therefore any increase in activity 
compared to HCT116 p53+/+ suggests an activity that is 
independent of p53. The Sensitivity Factors (SFs) have been 
calculated for the HCT116 cell lines, and shows all iridium 
compounds 1-9 are sensitive to the HCT116 p53-/- cell line, with 
SF values ranging from 1.07-26.71 (Table S8). The most striking 
result is observed for compound 4 against HCT116 p53-/-, which 
has a SF > 26, compared to cisplatin which is more sensitive 
towards the HCT116 p53+/+ cell line (SF = 0.43). Additionally, 
compound 4 is > 2.8 times more cytotoxic than cisplatin against 
HCT116 p53-/- (2.8 ± 0.2 PM (4) versus 8.1 ± 1.8 PM (cis)). 
Similar trends have been observed with iron helicate complexes, 
whereby the compounds are more sensitive to HCT116 p53-/-, 
and have IC50 values in the nanomolar range, however, a 
mechanistic understanding has not been reported yet.[26] The 
iridium compounds presented herein have the potential to be 
cytotoxic towards cisplatin resistant lines; however, further 
mechanistic studies are required to underpin the observed 
sensitivity and selectivity. 
Cytotoxicity after 24 and 48 hours 
Cell viability assays were conducted for selected compounds to 
assess their potential after short incubation periods. Compounds 
1, 4 and 9 were incubated for 24 h and 48 h with HCT116 p53-/- 
cells, and then a 96 h or 72 h recovery period was employed 
respectively. Even though the compounds are cytotoxic after 120 
h, they exhibit low to no activity after exposure for 24 or 48 h (IC50 
= 63-100 PM) contrary to cisplatin which is cytotoxic after these 
exposure times (IC50 = 10-15 PM) (Figure S7). 
Selectivity towards cancer cells 
As with cisplatin, a major limitation of new drug candidates is the 
cytotoxicity towards normal cells; this can limit the administrable 
dosages and can result in an increase of harmful side-effects. 
Compounds 1-9 were tested against normal prostate (PNT2) and 
normal retinal epithelial (ARPE-19) cell lines, to gain a preliminary 
indicatLRQ RI WKH FRPSRXQGV¶ FDQFHU VHOHFWLYLW\ Table 1). All 
complexes are only moderately cytotoxic towards PNT2, and a 
significant decrease in activity is observed against ARPE-19. As 
such, the compounds are confirmed to be non-toxic against 
ARPE-19 when tested at the maximum concentration (IC50 values 
= 71 ± 2 PM (6) and > 100 PM (1-5, 7-9)). Unlike cisplatin, which 
is toxic towards ARPE-19 (IC50 = 6 ± 1 PM), the iridium(III) 
compounds presented herein are > 11.8 times less cytotoxic 
towards this cell line, highlighting a potentially different mode of 
action. Additionally, the results have been expressed as 
Selectivity Ratios (SRs), which is defined as the ratio of the mean 
IC50 for the normal cells divided by the mean IC50 for each 
individual cancer cell line tested (Figure 3 and Tables S9-S10). 
As some of the IC50 values are > 100 PM, the SR cannot be stated 
exactly, therefore, the values are a minimal possible SR value. 
The most significant results are observed for compounds 4 and 9, 
which can be described as cancer selective, having a SR > 1, 
indicating a preferential selectivity towards tumor cells compared 
to normal cells. The SRs values against HCT119 p53-/- for 4 and 
9 are 14.07 and 3.97 (PNT2) and 35.59 and 20.28 (ARPE-19), 
respectively. The SR for cisplatin shows no selectivity for either of 
the normal cells and very low selectivity over cancerous cells, with 
SR ranging from 0.82-2.30 (PNT2) and 0.74-1.99 (ARPE-19). 
This further highlights these iridium compounds are active on 
different cell types than cisplatin, and could potentially combat 







Table 1. IC50 values (PM) ± SD for cisplatin and compounds 1-9 after a 120 h exposure with HCT116 p53+/+, HCT116 p53-/-, MIA PaCa-2, PNT2 and ARPE-
19. Results are the average of triplicate repeats. 
Compounds IC50 values (PM) ± SD 
HCT116 p53+/+ HCT116 p53-/- MIA PaCa-2 A549 PNT2 ARPE-19 
1 42 ± 2 37 ± 2 67 ± 2 > 100 41 ± 2 > 100 
2 80 ± 1 47 ± 2 > 100 > 100 55 ± 2 > 100 
3 19 ± 1 17.6 ± 0.3 37 ± 1  > 100 10.8 ± 0.3 > 100 
4 75 ± 2 2.8 ± 0.2 > 100 > 100  40 ± 4 > 100 
5 75 ± 4 23 ± 2 > 100 > 100  44 ± 2 > 100 
6 33 ± 1 6.6 ± 0.9 > 100 43 ± 1 20 ± 1 71 ± 2 
7 > 100 69 ± 2 > 100 > 100  > 100 > 100 
8 20.7 ± 0.2 17 ± 1 31.5 ± 0.7 > 100  > 100 > 100 
9 24 ± 2 4.9 ± 0.6 35 ± 1 52 ± 2 20 ± 1 > 100 
cisplatin 3.5 ± 0.5 8.1 ± 1.8 3.6 ± 0.7 3.0 ± 0.1 6.9 ± 0.3 6 ± 1 
[Cp*IrCl2(an)] >100 > 100 > 100  >100 > 100 > 100 
Figure 3. The selectivity ratio is defined as the IC50 in normal cells divided by 
IC50 relevant cancerous cells. An SR = 1 indicates equitoxic potency against 
tumor and normal cells. An SR > 1 indicates preferential selectivity for tumor 
cells compared to normal cells, whereas an SR < 1 indicates poor selectivity 
and a greater cytotoxicity towards normal cells. Bar-charts show SR for a) PNT2 
and b) ARPE-19. 
Inhibition of Thioredoxin Reductase 1 (Trx-R) 
The results of the MTT assay described above give a good 
indication of inhibition, but they do not provide information of cell 
growth, cell death or cell targets. As the biological effects of Trx-R 
have been shown to contribute to tumor growth and 
progression,[27] and the enzyme is over-expressed in several 
tumor types, the targeting of this enzyme can have important 
therapeutic results.[28±30] To gain a preliminary understanding of 
the potential targets, the inhibition of Trx-R was determined using 
WKH VXEVWUDWH ¶-dithiobis-(2-nitrobenzoic acid) (DTNB) as 
described elsewhere.[31] Compounds 4 and 9 were incubated with 
0.232 units of recombinant rat enzyme, however, these 
compounds did not show any inhibition of Trx-R, with IC50 values 
greater than the tested concentration (> 20 PM). contrary to our 
previously published work.[19] 
Conclusions 
This report presents a series of iridium complexes that have the 
potential to combat current issues of platinum toxicity towards 
normal cells. We have also highlighted that these compounds do 
not inhibit Trx-R, indicating a different mode of action as 
previously report iridium compounds. The most significant 
findings are the sensitivity of these compounds when tested 
against an isogenic pair of colorectal cancer, HCT116, in 
particular those which are p53-null, HCT116 p53-/-, showing a 
Sensitivity Factor (SF) up to 26 (compared to cisplatin SF = 0.43). 
Importantly, these compounds are non-toxic towards normal cell 
types, contrary to cisplatin which remains cytotoxic. We propose 
that these compounds are active via a p53 independent pathway, 





cancers, we have reason to believe these compounds could help 
target issues with mutant cell types. 
Experimental Section 
Synthesis of complexes 1-9. Complexes were synthesized by addition 
of [Cp*IrCl2]2 (0.5 eq.), to a stirring solution of a functionalized E-
ketoiminato ligand (1 eq.) and Et3N (1 eq.) in dichloromethane (30 mL). 
The mixtures were stirred overnight at room temperature and then the 
solvent removed under reduced pressure. The products were all 
recrystallized from methanol and obtained in 29-77% yields.  
X-ray Crystallography. A suitable single crystal was selected and 
immersed in an inert oil. The crystal was then mounted on a glass capillary 
or nylon loop and attached to a goniometer head on a Bruker X8 Apex 
diffractometer using graphite mono-chromated Mo-KD radiation (O = 
0.71073 Å) or an Agilent SuperNova diffractometer using mirror 
monochromated Mo-KD radiation (O = 0.71073 Å), using 1.0° I-rotation 
frames. The crystal was cooled to between 100-173 K by an Oxford 
Cryostream low temperature device.[32] The full data sets were recorded 
and the images processed using DENZO and SCALEPACK programs[33] 
or CrysAlis Pro software.[34] Structure solution by direct methods was 
achieved through the use of SHELXS programs,[35] and the structural 
models refined by full matrix least squares on F2 using SHELX97 unless 
otherwise stated. Hydrogen atoms were placed using idealized geometric 
SRVLWLRQVZLWKIUHHURWDWLRQIRUPHWK\OJURXSVDOORZHGWRPRYHLQD³ULGLQJ
moGHO´ DORQJ ZLWK WKH DWRPV WR ZKLFK WKH\ ZHUH DWWDFKHG DQG UHILQHG
isotropically. Molecular graphics, editing of CIFs and construction of tables 
of bond lengths and angles were all achieved using OLEX2. [36] 
Chemosensitivity Studies. In vitro chemosensitivity tests were 
performed at the Institute of Cancer Therapeutics, Bradford, against 
human colon colorectal carcinoma, p53-wildtype (HCT116 p53+/+) and 
p53-null (HCT116 p53-/-), human pancreas carcinoma (MIA PaCa-2) and 
human lung carcinoma (A549) cell lines. Growth inhibitory effects were 
also tested against normal prostate (PNT2) and normal retinal epithelial 
cells (ARPE-19). ARPE-19 was obtained from the American Type Culture 
Collection and kindly donated by Professor Roger Phillips and Dr Simon 
Allison (University of Huddersfield). All cells were routinely maintained as 
monolayer cultures in appropriate medium; RPMI 1640 supplemented with 
10% foetal calf serum for cell lines HCT116 +/+ and HCT116 -/-; high 
glucose DMEM-F12 medium containing 10% foetal calf serum for cell lines 
MIA PaCa-2 and ARPE-19; low glucose DMEM medium containing 10% 
foetal calf serum for the A549 cells line. All media was additionally 
supplemented with sodium pyruvate (1 mM) and L-glutamine (2 mM). For 
chemosensitivity studies, cells were incubated in 96-well plates containing 
100 PL cell suspensions at a concentration of 1 × 104 cells/well. The plates 
were incubated for 24 h at 37 °C in an atmosphere of 5% CO 2 prior to 
compound exposure (Lane 1 contains 100% media to serve as a blank). 
Complexes or cisplatin were each dissolved in DMSO to provide 100 mM 
stock solutions that were diluted to provide a range concentrations ranging 
from 200-1.56 PM. After 24 h, 100 PL of each compound/media mixture 
was added to the cells; so that the final DMSO concentrations were less 
than 0.1% (v/v) and final compound concentrations of 100-0.78 PM (Lane 
2 contains 100% cell suspension to serve as a control). The cells were 
incubated with the compound/media mixture a period of time (24, 48 or 
120 h, with a 96, 72 or 0 h recovery period respectively), at 37 °C in an 
atmosphere of 5% CO2. After the incubation period, 20 PL of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 5 mg/ mL) 
was added to each well and incubated for a further 3 hours at 37 °C in an 
atmosphere of 5% CO2. All solutions were then removed via pipette and 
 ȝ/ RI '062 DGGHG WR HDFK ZHOO LQ RUGHU WR GLVVROYH WKH SXUSOH
formazan crystals. Once mixed well via pipette, a Thermo Scientific 
Multiskan EX microplate photometer was used to measure the absorbance 
of each well at 540 nm. Using the blank and 100% cell control, the % cell 
viability was determined ((abs of compound containing wells ± abs media 
wells)/abs 100% cell suspension well control) and from this the % cell 
death (100% - % cell viability) can be calculated. On a logarithmic scale, 
the percentage cell death was plotted against the concentration of 
compound, and from this the half maximal inhibitory concentration (IC50) 
value was determined. Each of the experiments was performed in triplicate 
with mean values being stated as the IC50 ± Standard Deviation (SD). 
Inhibition of Thioredoxin Reductase Activity. Thioredoxin reductase 
sourced from rat liver was obtained from Sigma Aldrich. It is a buffered 
DTXHRXV JO\FHURO VROXWLRQ ޓ XQLWV PJ SURWHLQ 7KH HQ]\PH ZDV
dissolved in 50 mM Tris-HCl, pH 7.5, 300 mM NaCl, 1 mM EDTA, and 10% 
glycerol. The rate of change of UV-vis absorbance was measured at 412 
nm over 1 min to give the reaction velocity. The experiment was carried 
out using just the enzyme to get the control (no inhibitor) reaction velocity 
and then varying dilutions of the test compound were added up to a 
maximum of 20 PM. The reaction velocity in the presence of inhibitor was 
normalized relative to the control to generate % activity and plots of % 
activity versus concentration were constructed to obtain IC50 values 
(concentration that inhibited 50% of enzyme activity). 
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Colorectal cancer selective iridium 
drugs. This work presents new 
organometallic iridium(III) compounds 
which are sensitive to colorectal 
cancer cells, especially those with null 
p53 genes. Additionally, they are 
selective towards cancer cells over 
normal cells, contrary to cisplatin 
which is neither sensitive nor selective 
towards cancer. 
   Rianne M. Lord,* Markus Zegke, Imogen 
R. Henderson, Christopher M. Pask, 
Helena J. Shepherd, and Patrick C. 
McGowan 
Page No. ± Page No. 
E-Ketoiminato iridium(III) 
organometallic complexes: Selective 
cytotoxicity towards colorectal 
cancer cells HCT116 p53-/- 
 
  
 
 
 
 
